June 3 — 7, 2022 Chicago, IL

Booth #5063
1 Industry Expert Theater Session
3 Oral Presentations
3 Poster Highlight Sessions
7 Poster Presentations

ASCO® Annual Meeting 2022

Tempus’ mission is to apply data and AI to diagnostics in order to route every patient to a personalized, optimal therapeutic path. We’re helping treat the patients of today while finding cures for the patients of tomorrow. We are pleased to share our latest scientific and clinical research findings during the 2022 ASCO® Annual Meeting.

Schedule a meeting with us
Tempus Industry Expert Theater
June 6, 2022
live session
Time
09:30 am - 10:30 am CDT

Precision Oncology Now: Enhancing patient care with integrated clinical applications that are powered by multimodal data

Learn to empower your practice and research program through Tempus’ comprehensive portfolio of NGS offerings. Discover how one of the world’s largest cancer platforms accelerates discovery, provides personalized treatment options, and precisely matches patients to clinical trials.

Join the Tempus team at booth #5063 directly following the session for a live Q&A with the presenters, Dr. James Chen and Dr. Calvin Chao.

Oral Presentations and Poster Highlights
June 4, 2022
Poster #413

Time
08:00 am – 11:00 am CDT
First Author
Nina Sanford; UTSW

Genetic ancestry differences in tumor mutation and expression in early and average onset colorectal cancer

Used genetic ancestry instead of race/ethnicity classes to provide a more quantitative and precise profile of shared genetic background that can underlie biological race differences in cancer etiology and outcomes

Read more
June 5, 2022
Poster #130

Time
08:00 am – 11:00 am CDT
First Author
Christopher W. Seder; Rush University

Paired tumor/normal sequencing reduces apparent racial differences in tumor mutational burden (TMB)

The use of xT tumor/normal match reduced apparent discrepancy in TMB levels between racial groups, particularly for Black and Asian patients

Read more
live session
Poster #356

Time
08:00 am – 11:00 am CDT &
11:30 am – 01:00 pm CDT
Presenter
Robin Buerki; Northwestern

Real world data enables large-scale assessment of WHO CNS5 glioma classification

Researchers analyzed a de-identified dataset of CNS tumors and found that reclassifying according to the new WHO classification system resulted in more accurate prognostic stratification than the original diagnosis

Read more
live session
Poster #9

Time
08:00 am – 11:00 am CDT &
04:30 pm – 06:00 pm CDT
Presenter
Wade Iams; Vanderbilt

Dual tissue and plasma testing improves detection of actionable variants in patients with solid cancers

Performing liquid biopsy in addition to tissue based testing identifies more patients with clinically actionable variants

Read more
June 6, 2022
live session
Abstract #1504

Time
03:00 pm – 06:00 pm CDT
Presenter
Sibel Blau; Northwestern Medical

Operational Metrics for the ELAINE II study Combining a Traditional Approach with a Just-in-Time Model

By combining TIME trial and traditional enrollment models clinical trials may recruit more patients and reach full enrollment faster

Read more
live session
Poster #69

Time
03:00 pm - 06:00 pm CDT
Lead Author
Jack Michuda; Tempus Labs

Clinical RNA-sequencing improves the detection of actionable fusions over DNA-sequencing alone

In the largest fusion analysis of its kind Tempus reviewed a real-world data set of 77,400 patient records for improvement in clinically actionable fusion detection due to the inclusion of RNA sequencing; The inclusion of RNA sequencing improves fusion detection vs DNA alone

Read more
Poster Presentations
June 4, 2022
Poster #140

Time
08:00 am – 11:00 am CDT
Todd Knepper; Moffitt, Prateek Gulhati; Rutgers

Comparative Analysis of the Targetable Landscape in KRAS-mutated and wild-type Pancreatic Adenocarcinoma

Read more
Poster #149

Time
01:15 pm – 04:15 pm CDT
Jacob Koskimaki; Astrazeneca

Natural Language Processing-Optimized Case Selection for RWE Studies

Read more
June 5, 2022
Poster #58

Time
08:00 am – 11:00 am CDT
Mohamed E. Salem; Levine Cancer Institute

Comparative analysis of microsatellite instability-high (MSI-H) BRAF V600E–mutated versus MSI-H BRAF wild type colorectal cancers (CRC), including tumor microenvironment (TME), associated genomic alterations, and immuno-metabolomic biomarkers

Read more
Poster #110

Time
08:00 am – 11:00 am CDT
Brian Pham; UC Davis

Genomic landscape of SMARCA4-deficient lung tumors by clinical RNA sequencing

Read more
Poster #59

Time
08:00 am – 11:00 am CDT
Mohamed E. Salem; Levine Cancer Institute

Impact of RAS mutations on immunologic characteristics of the tumor microenvironment (TME) in patients with microsatellite instability-high (MSI-H) or mismatch-repair deficient (dMMR) colorectal cancer (CRC)

Read more
Poster #280

Time
08:00 am – 11:00 am CDT
Sukhmani Kaur Padda; Cedars Sinai

Prevalence of high tumor mutational burden (TMB-H) and microsatellite instability-high (MSI-H) status in neuroendocrine neoplasms.

Read more
Alexander Liede; University of Chicago

An analysis of EHR records to determine treatment patterns of women with advanced TNBC

Schedule a meeting with us

We'll be in touch shortly.